- You can view the full Alere Ratings Report.
- Use our health services section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
The deal comes as Abbott works to complete two pending transactions worth nearly $40 billion combined and is the latest in the slew of ophthalmology deals.
Abbott Labs shares have been all over the place in the last year as the company makes deals. Investors are wondering if they should hold on.
The cardiac device maker has filed a lawsuit against the Muddy Waters, claiming the short-seller intentionally disseminated false and misleading information.
Potential targets of the medical device and diagnostics giant might request stricter parameters when structuring a deal, company followers say.